Collin M. Blakely

8.5k total citations
75 papers, 2.1k citations indexed

About

Collin M. Blakely is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Collin M. Blakely has authored 75 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Collin M. Blakely's work include Lung Cancer Treatments and Mutations (46 papers), Cancer Genomics and Diagnostics (21 papers) and Colorectal Cancer Treatments and Studies (14 papers). Collin M. Blakely is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Cancer Genomics and Diagnostics (21 papers) and Colorectal Cancer Treatments and Studies (14 papers). Collin M. Blakely collaborates with scholars based in United States, Spain and Germany. Collin M. Blakely's co-authors include Michael G. Katze, Trever G. Bivona, Michael Gale, Seng-Lai Tan, Marcus J. Korth, Michelle L. Dossett, Stephen J. Polyak, Norina Tang, David R. Gretch and Robert C. Doebele and has published in prestigious journals such as Journal of Biological Chemistry, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Collin M. Blakely

71 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Collin M. Blakely United States 21 808 800 772 448 406 75 2.1k
Kazuyoshi Ohkawa Japan 29 710 0.9× 618 0.8× 259 0.3× 1.0k 2.2× 299 0.7× 158 2.4k
Guo‐Huan Yang China 17 732 0.9× 952 1.2× 217 0.3× 504 1.1× 773 1.9× 38 2.1k
Diana F. Hausman United States 18 584 0.7× 538 0.7× 310 0.4× 200 0.4× 101 0.2× 40 1.6k
Jeffrey J. Wallin United States 28 1.2k 1.5× 829 1.0× 483 0.6× 240 0.5× 228 0.6× 60 2.8k
Kazuaki Nakanishi Japan 25 565 0.7× 605 0.8× 394 0.5× 860 1.9× 269 0.7× 76 2.1k
Victoria Marcus Canada 26 824 1.0× 521 0.7× 307 0.4× 329 0.7× 411 1.0× 72 2.2k
Kris Ylaya United States 25 816 1.0× 1.0k 1.3× 362 0.5× 99 0.2× 527 1.3× 45 2.0k
Markus Rechsteiner Switzerland 24 572 0.7× 818 1.0× 457 0.6× 146 0.3× 597 1.5× 66 1.7k
Jiangchun Xu United States 22 429 0.5× 1.2k 1.5× 769 1.0× 80 0.2× 651 1.6× 27 2.3k
Atsushi Takai Japan 22 435 0.5× 560 0.7× 227 0.3× 395 0.9× 418 1.0× 69 1.5k

Countries citing papers authored by Collin M. Blakely

Since Specialization
Citations

This map shows the geographic impact of Collin M. Blakely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Collin M. Blakely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Collin M. Blakely more than expected).

Fields of papers citing papers by Collin M. Blakely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Collin M. Blakely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Collin M. Blakely. The network helps show where Collin M. Blakely may publish in the future.

Co-authorship network of co-authors of Collin M. Blakely

This figure shows the co-authorship network connecting the top 25 collaborators of Collin M. Blakely. A scholar is included among the top collaborators of Collin M. Blakely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Collin M. Blakely. Collin M. Blakely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blakely, Collin M., Jacqulyne Robichaux, Kyung‐Yul Lee, et al.. (2025). OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC. Journal of Thoracic Oncology. 20(10). S12–S13. 1 indexed citations
2.
Sinha, Sanju, Rahulsimham Vegesna, Sumit Mukherjee, et al.. (2024). PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nature Cancer. 5(6). 938–952. 48 indexed citations
3.
4.
Blakely, Collin M., et al.. (2024). Targeting MEK in non-small cell lung cancer. Current Problems in Cancer. 49. 101065–101065. 5 indexed citations
5.
6.
He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations
7.
Ali, Moiez, Min Lu, Ryan S. Soderquist, et al.. (2022). Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine. 14(638). eabc7480–eabc7480. 29 indexed citations
8.
9.
Blakely, Collin M., et al.. (2021). Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. Journal of Visualized Experiments. 3 indexed citations
10.
Yang, James Chih‐Hsin, Karen L. Reckamp, Young‐Chul Kim, et al.. (2020). Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports. 2(2). 100114–100114. 19 indexed citations
11.
Drilon, Alexander, Luis Paz‐Ares, Robert C. Doebele, et al.. (2020). 543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 31. S474–S475. 9 indexed citations
12.
McCoach, Caroline E., Collin M. Blakely, Kimberly C. Banks, et al.. (2018). Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(12). 2758–2770. 114 indexed citations
13.
Neel, Dana S., Victor Olivas, Manasi K. Mayekar, et al.. (2018). Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research. 79(3). 546–556. 63 indexed citations
14.
Spira, Alexander I., Collin M. Blakely, Kai He, et al.. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology. 29. viii400–viii401. 9 indexed citations
15.
Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 29. viii713–viii713. 46 indexed citations
16.
Doebele, Robert C., Kimberly C. Banks, Nnamdi Ihuegbu, et al.. (2017). P1.02-057 Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort. Journal of Thoracic Oncology. 12(1). S522–S522. 1 indexed citations
17.
McCoach, Caroline E., Trever G. Bivona, Collin M. Blakely, & Robert C. Doebele. (2016). Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non–Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer. 17(5). 466–469. 16 indexed citations
18.
Blakely, Collin M., Evangelos Pazarentzos, Victor Olivas, et al.. (2015). NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Reports. 11(1). 98–110. 143 indexed citations
19.
Blakely, Collin M. & Trever G. Bivona. (2012). Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance. Cancer Discovery. 2(10). 872–875. 31 indexed citations
20.
Blakely, Collin M., Alexander J. Stoddard, George K. Belka, et al.. (2006). Hormone-Induced Protection against Mammary Tumorigenesis Is Conserved in Multiple Rat Strains and Identifies a Core Gene Expression Signature Induced by Pregnancy. Cancer Research. 66(12). 6421–6431. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuyoshi Ohkawa Breakdown of academic impact, for papers by Guo‐Huan Yang Breakdown of academic impact, for papers by Diana F. Hausman Breakdown of academic impact, for papers by Jeffrey J. Wallin Breakdown of academic impact, for papers by Kazuaki Nakanishi Breakdown of academic impact, for papers by Victoria Marcus Breakdown of academic impact, for papers by Kris Ylaya Breakdown of academic impact, for papers by Markus Rechsteiner Breakdown of academic impact, for papers by Jiangchun Xu Breakdown of academic impact, for papers by Atsushi Takai
Rankless by CCL
2026